US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

92.83 -0.58 (-0.62%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rhythm Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Navigating 5 Analyst Ratings For Rhythm Pharmaceuticals ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Rhythm Pharmaceuticals ↗
 
Via Benzinga
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 4 Analysts ↗
 
Via Benzinga
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
RYTM Stock Earnings: Rhythm Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024 ↗
RYTM stock results show that Rhythm Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old
IMCIVREE now authorized as treatment of obesity and control of hunger in adult patients and pediatric patients 2 years old or older with Bardet Biedl syndrome or POMC, PCSK1, or LEPR deficiency 
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Analyst Expectations For Rhythm Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
5 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know ↗
 
Via Benzinga
News headline image
Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
IMCIVREE expected to be funded and available for use in England and Wales within three months through the National Health Service in specialist centres 
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
The 3 Best Nasdaq Stocks to Buy in May 2024 ↗
Although it’s typically the season for selling, shifting market conditions call for the best Nasdaq stocks to buy in May. 
Via InvestorPlace
News headline image
RYTM Stock Earnings: Rhythm Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 ↗
RYTM stock results show that Rhythm Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Jim Cramer Is 'Willing To Let This Pharma Stock Catch Fire,' Advises Not To Sell McKesson ↗
The "Mad Money" host recommended buying some Marvell Technology, and then wait until under $60 to buy the rest. 
Via Benzinga
News headline image
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >